BACKGROUND: 3,4-methylenedioxymethamphetamine (MDMA) therapy has qualities that make it potentially well suited for patients with addictions, but this has never been explored in a research study. We present data from the Bristol Imperial MDMA in Alcoholism (BIMA) study. This is the first MDMA addiction study, an open-label safety and tolerability proof-of-concept study investigating the potential role for MDMA therapy in treating patients with alcohol use disorder (AUD). AIMS: This study aimed to assess if MDMA-assisted psychotherapy can be delivered safely and can be tolerated by patients with AUD post detoxification. Outcomes regarding drinking behaviour, quality of life and psychosocial functioning were evaluated. METHODS: Fourteen patients with AUD completed a community alcohol detoxification and received an eight-week course of recovery-based therapy. Participants received two sessions with MDMA (187.5 mg each session). Psychological support was provided before, during and after each session. Safety and tolerability were assessed alongside psychological and physiological outcome measures. Alcohol use behaviour, mental well-being and functioning data were collected for nine months after alcohol detoxification. RESULTS: MDMA treatment was well tolerated by all participants. No unexpected adverse events were observed. Psychosocial functioning improved across the cohort. Regarding alcohol use, at nine months post detox, the average units of alcohol consumption by participants was 18.7 units per week compared to 130.6 units per week before the detox. This compares favourably to a previous observational study (the 'Outcomes' study) by the same team with a similar population of people with AUD. CONCLUSIONS: This study provides preliminary support for the safety and tolerability of a novel intervention for AUD post detox. Further trials to examine better the therapeutic potential of this approach are now indicated.
BACKGROUND: 3,4-methylenedioxymethamphetamine (MDMA) therapy has qualities that make it potentially well suited for patients with addictions, but this has never been explored in a research study. We present data from the Bristol Imperial MDMA in Alcoholism (BIMA) study. This is the first MDMA addiction study, an open-label safety and tolerability proof-of-concept study investigating the potential role for MDMA therapy in treating patients with alcohol use disorder (AUD). AIMS: This study aimed to assess if MDMA-assisted psychotherapy can be delivered safely and can be tolerated by patients with AUD post detoxification. Outcomes regarding drinking behaviour, quality of life and psychosocial functioning were evaluated. METHODS: Fourteen patients with AUD completed a community alcohol detoxification and received an eight-week course of recovery-based therapy. Participants received two sessions with MDMA (187.5 mg each session). Psychological support was provided before, during and after each session. Safety and tolerability were assessed alongside psychological and physiological outcome measures. Alcohol use behaviour, mental well-being and functioning data were collected for nine months after alcohol detoxification. RESULTS: MDMA treatment was well tolerated by all participants. No unexpected adverse events were observed. Psychosocial functioning improved across the cohort. Regarding alcohol use, at nine months post detox, the average units of alcohol consumption by participants was 18.7 units per week compared to 130.6 units per week before the detox. This compares favourably to a previous observational study (the 'Outcomes' study) by the same team with a similar population of people with AUD. CONCLUSIONS: This study provides preliminary support for the safety and tolerability of a novel intervention for AUD post detox. Further trials to examine better the therapeutic potential of this approach are now indicated.
Entities:
Keywords:
MDMA; alcohol use disorder; alcoholism; psychedelics; psychotherapy
Authors: Deborah Rudin; John D McCorvy; Grant C Glatfelter; Dino Luethi; Dániel Szöllősi; Tea Ljubišić; Pierce V Kavanagh; Geraldine Dowling; Marion Holy; Kathrin Jaentsch; Donna Walther; Simon D Brandt; Thomas Stockner; Michael H Baumann; Adam L Halberstadt; Harald H Sitte Journal: Neuropsychopharmacology Date: 2021-11-08 Impact factor: 8.294
Authors: Anna M Gutridge; Soumen Chakraborty; Balazs R Varga; Elizabeth S Rhoda; Alexander R French; Arryn T Blaine; Quinten H Royer; Haoyue Cui; Jinling Yuan; Robert J Cassell; Márk Szabó; Susruta Majumdar; Richard M van Rijn Journal: Front Pharmacol Date: 2021-11-03 Impact factor: 5.988
Authors: Bradford Martins; Will Rutland; Joao P De Aquino; Benjamin L Kazer; Melissa Funaro; Marc N Potenza; Gustavo A Angarita Journal: Curr Addict Rep Date: 2022-08-15
Authors: Joost J Breeksema; Bouwe W Kuin; Jeanine Kamphuis; Wim van den Brink; Eric Vermetten; Robert A Schoevers Journal: J Psychopharmacol Date: 2022-08-26 Impact factor: 4.562